摘要
背景:鸟苷酸环化酶C(GC-C)受体是一种跨膜受体,主要在肠上皮细胞中表达,其被认为在消化道的稳态和功能中起主要作用。该受体的内源性配体是旁分泌激素尿鸟苷素和鸟苷素。在配体结合后,GC-C受体增加环磷酸鸟苷(cGMP)水平,调节多种关键细胞类型特异性过程,例如氯化物和碳酸氢盐分泌,上皮细胞生长,肠屏障完整性调节和内脏敏感性。有人提出,GC-C作为一种肠道肿瘤抑制剂可能阻止结直肠癌的发生和发展。实际上,配体表达的丧失是散发性结直肠癌发生中的普遍步骤。有趣的是,GC-C的作用不仅限于消化道,而且已扩展到其他一些系统,例如心血管系统,肾脏和中枢神经系统,其中它涉及肠 - 下丘脑内分泌轴调节食欲。 目的:在这篇综述中,我们总结了GC-C受体及其配体的生理学,重点介绍了新开发的药物,如利那洛肽,以及他们提出的扭转/预防受体所涉及疾病的作用。 结论:现有的数据表明尿鸟苷素和鸟苷素及其受体和胃肠道和肾脏疾病,结直肠癌,肥胖症,代谢综合征和精神障碍等病理过程之间存在关系。 GC受体调节中的最新药理学发展可能涉及对相关疾病治疗的进一步改进。
关键词: 鸟苷酸环化酶C,热稳定肠毒素,腹泻,肠易激综合征,便秘,结肠直肠癌,肥胖症,炎症性肠病。
Current Medicinal Chemistry
Title:Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology
Volume: 25 Issue: 16
关键词: 鸟苷酸环化酶C,热稳定肠毒素,腹泻,肠易激综合征,便秘,结肠直肠癌,肥胖症,炎症性肠病。
摘要: Background: Guanylate cyclase C (GC-C) receptor is a transmembrane receptor, predominantly expressed in intestinal epithelial cells, which is considered to play a main role in homeostasis and function of the digestive tract. The endogenous ligands for this receptor are the paracrine hormones uroguanylin and guanylin. Upon ligand binding, GC-C receptors increase cyclic guanosine monophosphate (cGMP) levels, regulating a variety of key cell-type specific processes such as chloride and bicarbonate secretion, epithelial cell growth, regulation of intestinal barrier integrity and visceral sensitivity. It has been suggested that GC-C acts as an intestinal tumor suppressor with the potential to prevent the initiation and progression of colorectal cancer. In fact, loss of ligand expression is a universal step in sporadic colorectal carcinogenesis. Interestingly, the role of GC-C is not limited to the digestive tract but it has been extended to several other systems such as the cardiovascular system, kidney, and the central nervous system, where it has been involved in a gut-hypothalamus endocrine axis regulating appetite.
Objetive: In this review we summarize the physiology of the GC-C receptor and its ligands, focusing on newly developed drugs like linaclotide, and their suggested role to reverse/prevent the diseases in which the receptor is involved.
Conclusion: Available data points toward a relationship between uroguanylin and guanylin and their receptor and pathological processes like gastrointestinal and renal disorders, colorectal cancer, obesity, metabolic syndrome and mental disorders among others. Recent pharmacological developments in the regulation of GC-receptor may involve further improvements in the treatment of relevant diseases.
Export Options
About this article
Cite this article as:
Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology, Current Medicinal Chemistry 2018; 25 (16) . https://dx.doi.org/10.2174/0929867325666171205150310
DOI https://dx.doi.org/10.2174/0929867325666171205150310 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling
Current Medicinal Chemistry p53 as the Focus of Gene Therapy: Past, Present and Future
Current Drug Targets An Update of In Silico Tools for the Prediction of Pathogenesis in Missense Variants
Current Bioinformatics The Versatile Stress Protein Mortalin as a Chaperone Therapeutic Agent
Protein & Peptide Letters Enzalutamide: A Novel Anti-androgen with Prolonged Survival Rate in CRPC Patients
Mini-Reviews in Medicinal Chemistry Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
Current Drug Metabolism Yeast as a Model System to Study Trafficking of Small Vesicles Carrying Signal-less Proteins In and Out of the Cell
Current Protein & Peptide Science DNA Damage Repair and Response Proteins as Targets for Cancer Therapy
Current Medicinal Chemistry Targeting Angiogenesis in Gastro-Intestinal Non Colorectal Cancers; A Review
Current Angiogenesis (Discontinued) Dietary Phytochemicals in Chemoprevention of Cancer
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents New Strategies Against Prostate Cancer – Pt(II)-Based Chemotherapy
Current Medicinal Chemistry HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Current Cancer Drug Targets Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Current Medicinal Chemistry MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers
Current Pharmaceutical Design MicroRNAs in Genetic Disease: Rethinking the Dosage
Current Gene Therapy Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology